Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Short-term Investments (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Short-term Investments for 14 consecutive years, with $19.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Short-term Investments rose 112.44% to $19.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $19.6 million, a 112.44% increase, with the full-year FY2024 number at $14.9 million, changed N/A from a year prior.
  • Short-term Investments was $19.6 million for Q3 2025 at Gyre Therapeutics, up from $17.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $24.0 million in Q1 2021 to a low of $2.5 million in Q4 2021.
  • A 3-year average of $12.5 million and a median of $12.9 million in 2021 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: tumbled 94.89% in 2021, then surged 112.44% in 2025.
  • Gyre Therapeutics' Short-term Investments stood at $2.5 million in 2021, then skyrocketed by 495.05% to $14.9 million in 2024, then skyrocketed by 31.54% to $19.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Short-term Investments are $19.6 million (Q3 2025), $17.9 million (Q2 2025), and $14.8 million (Q1 2025).